Mike Thompson, MD, PhD, FASCO

Myeloma / PCD ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/5/25v2 - @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren @MyelomaTeacher @VincentRK @ManniMD1

Patients with high CAR-HEMATOTOX or m-EASIX scores had a significantly increased risk of prolonged hospitalization, antibiotic use, and fever during step-up dosing of bispecific TCE in RRMM #mmsm @RaabMarc aacrjournals.org/bloodcancerdis…

Join us for a live session exploring how foundation models move beyond single-purpose #AI to answer broader, more complex biological observations. Attendees will also learn more about our unique pathway from building a proof-of-concept model to deploying it directly into the clinic. Register here: tempus.co/4sfvenI

Happy Spring Equinox

A new case study details the significant, quantifiable improvements two community-based sites have seen across their research programs since joining the TIME network. Read now: tempus.co/4sgD8Nw

This might be the largest study of QOL in patients with NETs, the NET-PRO study -- 2,367 participants from multiple US centers (mean age 57.8 years; 57.3% female) -- 1,974 with GEP-NETs (659 SI-NET, 555 pNET) and 393 with lung NETs -- Fatigue (mean 33.0), insomnia (32.5), and diarrhea (25.7) were the most burdensome symptoms -- Lung NET patients reported worse dyspnea (SMD = 0.58, p < 0.001) and lower physical, role, and global QoL scores than those with GEP-NETs -- Diarrhea worsened over time, especially in SI-NETs. --- Most rated care highly (75.3%) but cited concerns about treatment side effects (80.4%), costs (60.7%), and travel burden (58.8%). Very informative and more is on its way from this group. Thanks to the NET-PRO group for this herculean effort which is still ongoing. academic.oup.com/jnci/advance-a…

Join us at @TheUSCAP Annual Meeting to explore our comprehensive pathology offerings and latest research. Combining Paige’s industry-leading digital pathology expertise with the broader Tempus ecosystem, we are redefining what’s possible in AI-enabled pathology to empower anatomic and molecular pathologists worldwide. #USCAP2026 Head to booth #542 and learn more here: tempus.co/40H00K5

Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time. "Can I get MMR 💉 on dara-len maintenance?" Short answer: 💯%, it seems! Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm

Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases [May 14, 2024] Aparicio et al. @BrJCancer nature.com/articles/s4141… #sbcsm #cagenome HT @OncoThor

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study [Sep 29, 2023] Zaanan et al. @JNCI_Now Cancer Spectrum academic.oup.com/jncics/article… #sbcsm

Cancer Tag Ontology (CTO) - ow.ly/LSlFx [6/7/24] Proposed: #sbcsm = small bowel cancer social media cc @michael_overman @OncoThor @skopetz @subatomicdoc

Iron deficiency symptoms precede anemia because the body prioritizes red cell production — other tissues become iron-deficient first.

Enhancing Clonal Hematopoiesis Variant Detection in Tumor-Normal Matched Sequencing Using Machine Learning [Mar 25, 2025] Sonnenschein et al. #AACR25 Abst 2388 tempus.com/publications/e…

Excited to share this viewpoint @JAMAOnc on how NGS testing barriers impact timely lung cancer management! jamanetwork.com/journals/jamao…

Just as an LLM predicts the word “run” when it sees “see spot,” models can now be trained to predict what comes next for a patient. But there’s a catch: to predict a patient's journey, you need to have seen it before. You need longitudinal data, outcome responses, and molecular insights at scale. We’ve spent a decade amassing connected data because we believe the "holy grail" of AI isn't just rewriting emails, it's preventing a patient from suffering because they are on the wrong treatment. Read more on my latest blog: lefkofsky.com/see-spot-run/

Ok so when I called this place a hellsite …

We're thrilled to announce a strategic collaboration with @BloodCancerUtd to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Learn more: tempus.co/4sVBPnr

#mmsm #bmtsm #caxtx